Sponsors (12)
The bill aims to speed patient access and reduce regulatory burden for certain protein-containing products by narrowing biologics classification, but it raises safety risks from reduced oversight and legal uncertainty about what counts as a 'clinically inactive' component.
Patients with chronic conditions and hospitals/health systems could get faster access to certain protein-containing therapeutics because FDA would have clearer grounds to avoid automatically classifying products with clinically inactive proteins as biologics.
Manufacturers, developers, and researchers would face reduced regulatory uncertainty because products containing clinically inactive proteins would not be automatically regulated as biological products.
Patients with chronic conditions and hospitals/health systems could face greater safety risk if limiting FDA's ability to classify products reduces oversight and misses unrecognized biological effects of so‑called clinically inactive proteins.
Manufacturers, researchers, and HHS could face legal disputes and added compliance costs because ambiguities over what qualifies as a 'clinically inactive component' may invite litigation and regulatory uncertainty.
Based on analysis of 2 sections of legislative text.
Changes the PHSA definition so a clinically inactive protein alone cannot make a product a "biological product."
Changes the federal statutory definition of "biological product" to say that a product does not become a biological product merely because it contains a protein that is a clinically inactive component. The amendment adjusts punctuation in the existing text and adds this rule to limit when the Public Health Service Act treats items as biologics for regulatory purposes.
Official title: To amend the Public Health Service Act to prohibit treatment of a biologic as a biological product based solely on the presence of a protein that is a clinically inactive component in such biologic, and for other purposes.
Introduced April 30, 2026 by Michael A. Rulli · Last progress April 30, 2026